The status of platinum anticancer drugs in the clinic and in clinical trials - Wikidata - wikimedia - TriplyDB

The status of platinum anticancer drugs in the clinic and in clinical trials

The status of platinum anticancer drugs in the clinic and in clinical trials

http://www.wikidata.org/entity/Q28286605

about

Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile Advances in drug delivery system for platinum agents based combination therapy Redox activation of metal-based prodrugs as a strategy for drug delivery Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs Carbon nanotubes as cancer therapeutic carriers and mediators Determinants for simultaneous binding of copper and platinum to human chaperone Atox1: hitchhiking not hijacking Prediction of cancer drugs by chemical-chemical interactions Methylseleninic acid sensitizes Notch3-activated OVCA429 ovarian cancer cells to carboplatin 1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug The elements of life and medicines Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer Disturbance of DNA conformation by the binding of testosterone-based platinum drugs via groove-face and intercalative interactions: a molecular dynamics simulation study.Early therapy assessment of combined anti-DR5 antibody and carboplatin in triple-negative breast cancer xenografts in mice using diffusion-weighted imaging and (1)H MR spectroscopy Amide coupling reaction for the synthesis of bispyridine-based ligands and their complexation to platinum as dinuclear anticancer agents An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.Targeting DNA Mismatches with Rhodium Metalloinsertors.A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo.Cytotoxicity of Pyrazine-Based Cyclometalated (C^Npz^C)Au(III) Carbene Complexes: Impact of the Nature of the Ancillary Ligand on the Biological Properties.Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer.Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion.Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage.Synthesis and characterization of novel bis(carboxylato)dichloridobis(ethylamine)platinum(IV) complexes with higher cytotoxicity than cisplatin Conjugates of cisplatin and cyclooxygenase inhibitors as potent antitumor agents overcoming cisplatin resistance.Using Drosophila melanogaster to identify chemotherapy toxicity genes.Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C(∧)N-Chelated and Pyridine Ligands.Nanocarriers for delivery of platinum anticancer drugs.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Understanding and improving platinum anticancer drugs--phenanthriplatin The interaction of platinum-based drugs with native biologically relevant proteins.Trial Watch: Peptide-based anticancer vaccines.The ex vivo neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles.Synthesis, characterization, interaction with DNA and cytotoxicity of Pd(II) and Pt(II) complexes containing pyridine carboxylic acid ligands.A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy Lobaplatin inhibits growth of gastric cancer cells by inducing apoptosis Synthesis, characterization, and cytotoxicity of platinum(IV) carbamate complexes Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy

P2860

Q24625759-B56032D2-40B9-4949-B28F-1601C1BDDB9E Q26771390-55E1E023-285C-4253-ABA6-36B55CC80C1A Q27025736-6140FA53-7FFB-4E33-8058-2F08346221D9 Q27678705-E71FEAD5-715D-4669-BB66-BC4AE4892E4F Q27702884-80027D28-1BA8-453C-83FA-82EBFC9A8FCE Q28066801-D05B89EF-D11F-4679-A580-37E39633459A Q28074309-3C11FE8A-8D0E-408F-82FE-1339A28CA752 Q28534972-6E8F9890-063A-4D4B-BD7D-B469768F2DC1 Q28539449-E16BE2D7-87EF-46D9-8F44-CB20522125B7 Q28540634-9D2F76C6-7301-4B9E-9ABB-9C84CF6D6C69 Q28547627-ED0B871C-37FF-4BD9-9DAD-0661A59275D3 Q28649323-25BE502A-BAD1-490A-AE2B-F3C53D5E6E3B Q30238915-FE56D3A9-0CB1-4197-84E1-1B3FD4387D0B Q30538107-C7F32660-659B-4A93-80AD-67F62C9427D6 Q30682911-E5B78C37-8E49-41AA-B2DD-C7FEC33BA513 Q30828730-C549F660-9ED3-4161-9DDB-0A1FA363F472 Q30855124-29869998-E1D8-49EB-985C-F5D5E0D8CE9D Q31136996-8603811D-769D-4F88-B320-0FC2D7AAA284 Q33415717-98C99A1B-2F56-4FC0-A0EB-D435407168AB Q33615268-95E323F5-F108-45B7-AA21-D2E6C0EC5F04 Q33696556-5F4C515E-C6AD-4E4E-B649-C9C0CE363240 Q33716280-F1E36FAD-10ED-41E9-ADEC-AACAAC0ECE93 Q33798812-DB2213FA-532B-4713-B29B-F88838744E28 Q33825880-9B5F3C1F-7F04-44C7-BF34-8971581CFC6C Q33917124-7291A8DC-917A-4400-A824-6B4EF5BC5AE8 Q34028040-A12D222C-3C8E-4A84-A17F-D7A4ECDAA5BC Q34060461-5CC4D6AC-4ACF-4A0E-9DEC-A10112223CB5 Q34242959-2417410E-E276-49ED-94C9-186413BF754D Q34331245-367638E3-C55B-4176-A058-4243F1DBF4EC Q34338695-A576D01E-3608-413B-BC58-5E976D5EAE6C Q34377003-2BD8BB2B-6E9F-47CE-8D01-18F4601D48B1 Q34396623-F597F60F-6873-4D49-8677-3270A263E02C Q34439746-3B9BD082-3436-42BD-8C0A-C1593D3B561E Q34483345-EF0E0A6A-E1AF-46DE-85A8-9CF466F2B25E Q34523282-A7FDB35A-FBB0-4749-9062-EEA624A0A544 Q34555057-6BBB0F2C-FA61-4EC6-90A4-04E8EC51B41D Q34583261-01EFE785-9325-427A-809B-B23BCBB8BBA5 Q34696650-95FACBD6-B710-480C-9FBB-E83DC2CF645F Q34731239-E0DBB846-CCBD-471E-A223-C8CD36DD9861 Q34791190-E6E8E02C-B2EE-4391-B11C-A630E9C65A19

P2860

The status of platinum anticancer drugs in the clinic and in clinical trials

http://www.wikidata.org/entity/Q28286605

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

The status of platinum anticancer drugs in the clinic and in clinical trials

@ast

The status of platinum anticancer drugs in the clinic and in clinical trials

@en

The status of platinum anticancer drugs in the clinic and in clinical trials

@nl

type

label

The status of platinum anticancer drugs in the clinic and in clinical trials

@ast

The status of platinum anticancer drugs in the clinic and in clinical trials

@en

The status of platinum anticancer drugs in the clinic and in clinical trials

@nl

prefLabel

The status of platinum anticancer drugs in the clinic and in clinical trials

@ast

The status of platinum anticancer drugs in the clinic and in clinical trials

@en

The status of platinum anticancer drugs in the clinic and in clinical trials

@nl

P1433

Q28286605-E741192C-3D57-44F9-99A7-6310A28824ED

P1476

Q28286605-6AFA2933-CE7C-4B45-8080-4932A9C018D5

P2093

Q28286605-4FD24FC6-8F5C-4604-87E0-99EE8E5A33F5

Q28286605-E7688D89-CCA0-43A0-8920-98B3EF7E8043

Q28286605-FDFCBFA9-E0F6-40C6-8A12-3719B4274B14

P2860

Q28286605-62556773-90A9-4BAE-8163-2AF987606E38

Q28286605-8E9322F5-2EF3-4783-9751-45FB006E33D1

Q28286605-9F3CCA93-67F3-4D76-82B1-382DB0890C91

Q28286605-BAE91E6A-86A0-4C54-A392-C8FA108D1D67

Q28286605-BD1304CB-7DB4-46B2-8CAF-DF0F71940A9A

Q28286605-FE995DE4-D33E-481E-A940-E058BB4A9CAC

P304

Q28286605-6705D25C-E294-4747-A057-4B15A4E22849

P31

Q28286605-29F1DC27-5D71-4DFD-98D1-AFFC061CFD95

P3181

Q28286605-5CB5A5A3-A1C9-4187-A885-3421FE002B64

P356

Q28286605-7FB1894E-047E-40F9-8C19-2A860C733132

P407

Q28286605-5D990A1C-6C22-4659-ACCA-4E49C02F5DD5

P433

Q28286605-123ACF7A-C410-4640-ACE1-8B1EB5DA4FB9

P478

Q28286605-33AE8F8A-9B40-487F-ABBE-9D20A9DE4D87

P50

Q28286605-87B8265E-D95B-4DAC-8BF0-37DE56C74E69

P577

Q28286605-C0C6E845-3651-4D6F-AF4D-A8B3582C4BE0

P698

Q28286605-B27268E4-297B-4CA3-85D9-DD882CDFCB5D

P3181

P356

P1433

Dalton Transactions

P1476

The status of platinum anticancer drugs in the clinic and in clinical trials

@en

P2093

Gemma E Craig

http://www.w3.org/2001/XMLSchema#string

Rabbab Oun

http://www.w3.org/2001/XMLSchema#string

Shonagh Walker

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer.

A phase I study of 1,2-diamminomethyl-cyclobutane-platinum (II)-lactate (D-19466; lobaplatin) administered daily for 5 days.

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Potent antitumour activity of (-)-(R)-2-aminomethylpyrrolidine (1,1-cyclobutanedicarboxylato)platinum(II) monohydrate (DWA2114R) against advanced L1210 leukaemia in mice.

Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study.

P304

8113-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

151674

http://www.w3.org/2001/XMLSchema#string

P356

10.1039/C0DT00292E

http://www.w3.org/2001/XMLSchema#string

P407

P433

35

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20593091

http://www.w3.org/2001/XMLSchema#string